Ask about this productRelated genes to: CYP2D6 antibody
- Gene:
- CYP2D6 NIH gene
- Name:
- cytochrome P450 family 2 subfamily D member 6
- Previous symbol:
- CYP2DL1, CYP2D7P2, CYP2D7BP, CYP2D8P2, CYP2D7AP
- Synonyms:
- CPD6, P450-DB1, CYP2D, P450C2D
- Chromosome:
- 22q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-07
- Date modifiied:
- 2019-04-23
Related products to: CYP2D6 antibody
Related articles to: CYP2D6 antibody
- Decision trees can use clinical predictors to determine whether to continue the same antidepressant or switch to a different treatment in older patients with major depressive disorder (MDD). We examined whether pharmacogenetic and pharmacokinetic variables could improve their performance. - Source: PubMed
Publication date: 2026/04/28
Kim Helena KMen XiaoyuElsheikh Samar S MMüller Daniel JBlumberger Daniel MKarp Jordan FLenze Eric JRamsey Laura BReynolds Charles FTaylor Zachary LMulsant Benoit H - : Tamoxifen is widely used in the treatment of hormone receptor-positive breast cancer and has been shown to successfully reduce recurrence and mortality rates. Nonetheless, variability in patient response to tamoxifen treatment is observed with up to 40% of patients experiencing recurrence. Genetic polymorphisms in pharmacogenes encoding enzymes involved in tamoxifen metabolism have been linked to some of this observed interindividual variability. The pharmacogenetics of tamoxifen in populations of African descent remain understudied, creating difficulties in pinpointing the primary factors behind the observed variable response. To address this gap, this study aimed to investigate the role of genetic variation in tamoxifen treatment outcomes in a South African cohort. : Participants included 166 Mixed and African Ancestry breast cancer patients who had received tamoxifen treatment. Genetic characterization was performed for 53 single nucleotide polymorphisms (SNPs) and two copy number variations across eight drug-metabolizing enzymes, including cytochrome P450s (, , , ), UDP-glucuronosyltransferases (), and sulfotransferases (, , ). The association between genotypes and disease-free survival (DFS) was evaluated using Cox proportional hazards regression models. : The or * genotype showed a nominal association with improved DFS ( = 0.049), with a similar trend observed for rs11888492. In contrast, rs3775779 heterozygosity showed a nominal association with reduced DFS ( = 0.044). SNPs (rs4149393, rs4149394, rs1042157) demonstrated trends toward reduced DFS. : These exploratory findings highlight the need for more inclusive pharmacogenomic research and point to potential biomarkers for optimizing tamoxifen therapy in African populations. - Source: PubMed
Publication date: 2026/03/31
Kruger BiancaChimusa Emile RAbera Aron BSingh JesmikaShamley DelvaDandara Collet - Malaria, particularly by , remains a significant public health challenge in endemic regions. has the dormant liver-stage hypnozoites that can reactivate, causing relapses, even after the initial blood-stage infection has been cleared. The prevention of these relapses hinges on the use of 8-aminoquinolines such as primaquine (PQ) and tafenoquine (TQ). However, the efficacy of these treatments is associated with Cytochrome P450 2D6 () activity, which influences drug metabolism. This case-control study aimed to evaluate the relationship between activity and the efficacy of TQ and PQ in preventing relapses. Patients with malaria were included in a nested case-control cohort study conducted at the Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (Manaus, AM, Brazil). Participants were classified as cases (recurrent malaria within 180 days) or controls (patients without recurrence). They were treated with PQ or TQ. Epidemiological data were collected from participants, and blood samples were obtained for genotyping by real-time PCR. The results showed that polymorphisms did not affect TQ efficacy ( = 0.172). However, participants treated with PQ had a higher risk of recurrence until six months ( = 0.016). Those with a predicted intermediate or poor metabolizer phenotype (gIM + gPM) were more likely to experience recurrence compared to normal metabolizers (gNM) ( = 0.036). Our findings indicate that does not impact the efficacy of TQ, whereas recurrence is associated with predicted metabolic phenotype, with increased risk among patients treated with PQ, suggesting that variability influences treatment response, particularly in intermediate/poor metabolizers. - Source: PubMed
Publication date: 2026/04/27
Godinho Vanessa Karina CastroMwangi Victor IrunguMorais Manuela CrispimLopes Adriana Patricia BrelazAlves Jessica Rafaela Dos SantosBrito Marcelo Augusto MotaLacerda Marcus Vinicius Guimarães deTrindade Maranhão Costa FabioAlmeida Anne Cristine Gomes deMelo Gisely Cardoso de - Although combined plasma levels of imipramine and its metabolite desipramine are routinely assessed during therapeutic drug monitoring (TDM) of imipramine treatment, individual plasma levels are often overlooked. Imipramine and desipramine differ in their pharmacokinetic properties. Previous research in patients with generalized anxiety disorder suggested that imipramine treatment efficacy might be negatively influenced by high desipramine levels. We thus explored the relationship between imipramine and desipramine levels and treatment response in depressed inpatients. - Source: PubMed
Publication date: 2026/04/27
Kasanmonadi Roan Y NKamperman Astrid MKoch Birgit C PBirkenhager Tom K - The aim of this study was to elucidate cardiovascular prescriber access, uptake, and attitudes toward CYP2C19 and CYP2D6 genetic testing to guide prescribing of commonly used medications such as clopidogrel, antiarrhythmics, proton pump inhibitors, and antidepressants. A survey, designed in collaboration with the European Society of Cardiology (ESC) WG on Cardiovascular Pharmacotherapy and external experts was disseminated to ESC members using SurveyMonkey. 265 prescribers from 68 countries participated. Most respondents thought testing would be beneficial, though CYP2C19 testing was perceived as more beneficial (73%) and desirable than CYP2D6 (61%). Access to CYP2C19 testing was more common (30%) than CYP2D6 testing (19%), but mostly outside of public funded health systems. Uptake in those who had access was higher for CYP2C19 (67%), than for CYP2D6 (33%). Confidence in interpreting results to prescribe was also higher with CYP2C19 (69%) than with CYP2D6 (53%), but most respondents wanted information prior to prescribing. One third of respondents highlighted the need for a turnaround time that matched their clinical practice. Unsolicited Pharmacogenomic (PGx) information from a patient was uncommon, but most prescribers acted on the information. A minority of respondents had undertaken PGx testing themselves, but most wanted testing for relevant medications. Respondents' experiences as patients made them more likely to believe that PGx testing was warranted. A minority ( ~ 15%) were aware of either local prescriber guidance or patient information materials regarding PGx testing. Prescribers want access to pharmacogenomics data regarding CYP2C19 and CYP2D6 for prescribing cardiovascular medicines. However, there are barriers which hamper implementation. Prescribers lived experience with medication use as patients impacted their views of PGx. 265 prescribers responded to the ESC survey from 68 countries. Most prescribers wanted access to pharmacogenomic testing for CYP2C19 and CYP2D6 for their patients and for themselves. Though most prescribers thought these pharmacogenomic tests would be useful and could improve the risk/benefit profile of relevant medications, prescribers responded more positively to CYP2C19 compared with CYP2D6 testing. Guidance and information for both prescribers and patients were lacking. - Source: PubMed
Publication date: 2026/04/23
Magavern Emma FDan G-AndreiSavarese GianluigiBorghi ClaudioDobrev DobramirTamargo JuanFerdinandy PeterMcDermott John HNewman William GPirmohamed MunirCaulfield Mark JKaski Juan Carlos